# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Laidlaw & Co. analyst Yale Jen maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price target from $15 to $25.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...
Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10...
Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate a...
Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 stud...